Literature DB >> 33395526

Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1.

Adam D Cotton1, Duy P Nguyen1, Josef A Gramespacher1, Ian B Seiple1,2, James A Wells1.   

Abstract

Targeted protein degradation has emerged as a new paradigm to manipulate cellular proteostasis. Proteolysis-targeting chimeras (PROTACs) are bifunctional small molecules that recruit an E3 ligase to a target protein of interest, promoting its ubiquitination and subsequent degradation. Here, we report the development of antibody-based PROTACs (AbTACs), fully recombinant bispecific antibodies that recruit membrane-bound E3 ligases for the degradation of cell-surface proteins. We show that an AbTAC can induce the lysosomal degradation of programmed death-ligand 1 by recruitment of the membrane-bound E3 ligase RNF43. AbTACs represent a new archetype within the PROTAC field to target cell-surface proteins with fully recombinant biological molecules.

Entities:  

Year:  2021        PMID: 33395526     DOI: 10.1021/jacs.0c10008

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  25 in total

Review 1.  Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics.

Authors:  Hirohito Yamaguchi; Jung-Mao Hsu; Wen-Hao Yang; Mien-Chie Hung
Journal:  Nat Rev Clin Oncol       Date:  2022-02-07       Impact factor: 66.675

2.  Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins.

Authors:  Katarina Pance; Josef A Gramespacher; James R Byrnes; Fernando Salangsang; Juan-Antonio C Serrano; Adam D Cotton; Veronica Steri; James A Wells
Journal:  Nat Biotechnol       Date:  2022-09-22       Impact factor: 68.164

Review 3.  Major Advances in Emerging Degrader Technologies.

Authors:  Hang Luo; Li Wu; Yujian He; Chong Qin; Xinjing Tang
Journal:  Front Cell Dev Biol       Date:  2022-06-22

4.  Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations.

Authors:  Daniel R Principe
Journal:  Sci Rep       Date:  2022-07-07       Impact factor: 4.996

Review 5.  Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation.

Authors:  Camilla Ruffilli; Sascha Roth; Monica Rodrigo; Helen Boyd; Noam Zelcer; Kevin Moreau
Journal:  ACS Pharmacol Transl Sci       Date:  2022-09-05

Review 6.  Degradation from the outside in: Targeting extracellular and membrane proteins for degradation through the endolysosomal pathway.

Authors:  Green Ahn; Steven M Banik; Carolyn R Bertozzi
Journal:  Cell Chem Biol       Date:  2021-03-25       Impact factor: 9.039

7.  Cancer Selective Target Degradation by Folate-Caged PROTACs.

Authors:  Jing Liu; He Chen; Yi Liu; Yudao Shen; Fanye Meng; H Ümit Kaniskan; Jian Jin; Wenyi Wei
Journal:  J Am Chem Soc       Date:  2021-05-10       Impact factor: 16.383

8.  Post-translational regulations of PD-L1 and PD-1: Mechanisms and opportunities for combined immunotherapy.

Authors:  Xiaoming Dai; Yang Gao; Wenyi Wei
Journal:  Semin Cancer Biol       Date:  2021-04-05       Impact factor: 17.012

Review 9.  Targeted protein degradation: A promise for undruggable proteins.

Authors:  Kusal T G Samarasinghe; Craig M Crews
Journal:  Cell Chem Biol       Date:  2021-05-17       Impact factor: 9.039

Review 10.  Antibody-based cancer therapy.

Authors:  Rebecca S Goydel; Christoph Rader
Journal:  Oncogene       Date:  2021-05-04       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.